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Abstract
Background: Embryo implantation plays a major role in embryogenesis and the outcome of
pregnancy. Plasminogen activators (PAs) have been implicated in mammalian fertilization, early
stages of development and embryo implantation. As in-vitro developing embryos resulted in lower
implantation rate than those developed in-vivo we assume that a reduced PAs activity may be
involved.
In the present work we studied the effect of EGF on PAs activity, quantity and embryo implantation.
Methods: Zygotes were flushed from rat oviducts on day one of pregnancy and grown in-vitro in
R1ECM supplemented with EGF (10 ng/ml) and were grown up to the blastocyst stage. The control
groups were grown in the same medium without EGF. The distribution and quantity of the PAs
were examined using fluorescence immunohistochemistry followed by measurement of PAs
activity using the chromogenic assay. Implantation rate was studied using the embryo donation
model.
Results: PAs distribution in the embryos was the same in EGF treated and untreated embryos.
Both PAs were localized in the blastocysts' trophectoderm, supporting the assumption that PAs
play a role in the implantation process in rats.
EGF increased the quantity of uPA at all stages studied but the 8-cell stage as compared with
controls. The tissue type PA (tPA) content was unaffected except the 8-cell stage, which was
increased. The activity of uPA increased gradually towards the blastocyst stage and more so due to
the presence of EGF. The activity of tPA did not vary with the advancing developmental stages
although it was also increased by EGF.
The presence of EGF during the preimplantation development doubled the rate of implantation of 
the treated group as compared with controls.
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Background
The major obstacle in IVF treatments is the low embryo
implantation rate. The composition of the embryo culture
medium supposed to mimic the physiological environ-
ment, addition of growth factors to the medium may be
vital not only for improving the embryo development but
also for increasing the embryo implantation rates in IVF
programs. Plasminogen activators are members of one of
the main enzyme family that participate in embryo
implantation.
Plasminogen activators (PAs) and matrix metalloprotein-
ases (MMPs) have been implicated in mammalian game-
togenesis [1], ovulation [2,3], fertilization [4,5], early
development and embryo implantation [3,6,7]. The PAs
are serine proteases, which convert the inactive plasmino-
gen to the potent protease plasmin. Plasmin can degrade
directly or indirectly, through the activation of metallo-
proteinase zymogens, all components of the extracellular
matrix [8,9].
There are two types of PAs, the tissue-type plasminogen
activator (tPA) and the urokinase-type plasminogen acti-
vator (uPA). Plasminogen, its activators and inhibitors
participate in the implantation process. Trophoblast cells
of mouse blastocysts cultured in-vitro produced PAs dur-
ing the period corresponding to the in-vivo invasion into
the endometrium [10]. In embryos of the homozygous
tw73 mouse mutant, PAs were reduced and were concom-
itantly associated with implantation failure [11]. The
invasion of trophoblast cells during the implantation
process could be blocked by inhibitors of serine proteases,
illustrating the role of these enzymes in the invasion proc-
ess [12,13].
In the human, embryo implantation is considered to be
one of the most critical steps in reproduction. An esti-
mated 30–70% of embryos are lost prior to or during
implantation [14]. In in-vitro fertilization-embryo trans-
fer (IVF-ET) programs only 12% of the transferred
embryos successfully implant [15].
In the implantation process, two major factors participate:
the uterus undergoes changes that prepare it for the arrival
and implantation of embryos, and the embryos which
undergo cellular reorganization that enables them to pen-
etrate the endometrium and to form the placenta. We
assume that one of the reasons for low implantation rate
of in-vitro developing embryos involves reduced PAs
activity.
Preimplantation embryos express variety of growth factors
and their receptors [16]. These include Epidermal Growth
Factor (EGF) receptors, which are expressed during the
preimplantation stage by murine [17], porcine [18] and
human embryos [19]. Many attempts have been made to
determine whether preimplantation development, cleav-
age, and differentiation of the blastocyst are influenced by
either endogenous or exogenous growth factors.
Among these growth factors, EGF has been shown to stim-
ulate both cellular proliferation and differentiation [20].
Several reports demonstrated the effect of EGF as a mito-
sis-promoting agent on perimplantation embryo develop-
ment. EGF was found to improve the preimplantation
embryo development by increasing cell metabolism and
proliferation [21]. In media enriched with EGF (and other
factors of the EGF family), higher blastocyst rates as well
as improved trophectoderm expansion were demon-
strated [16]. It was found that addition of EGF to mice cul-
tured preimplantation embryos stimulated DNA and RNA
synthesis and increased cell numbers [21]. Translational
inhibition of the EGF-receptor mRNA by anti-sense RNA
treatment leads to a delay in blastocyst formation [22].
However, very few studies on the effect of EGF during pre-
implantation development of embryos of species other
than mouse are reported.
Despite the beneficial effects of growth factors on preim-
plantation embryo development, more recent medium
formulations, particularly those containing amino acids,
but no growth factors, have resulted in rates of develop-
ment that approximate those occurring in-vivo, with
nearly 100% of embryos forming blastocysts [23,24].
These embryos have an increased cell number, develop a
primitive endoderm, and the levels of gene expression are
quantitatively and qualitatively similar to those in in-vivo
grown embryos [25].
In this study we examined the effects of exogenous EGF on
the expression and activity of tPA and uPA in preimplan-
tation embryos developed in-vitro, and we compared the
implantation rate of these embryos to in-vitro developed
once that were unexposed to EGF.
Methods
The following study was approved by the Institutional
committee for animal care and ethics at Ben-Gurion Uni-
versity of the Negev, Beer-Sheva, Israel, before the com-
mencement of the experiments.
Animals
Mature female Wistar rats 2–3 months old, weighing 180–
230 g were used. The animals were kept in a temperature-
controlled room maintained at 22–24°C with lighting
regimen of 14 hours light 10 hours dark (light on 5:00 AM
– 7:00 PM). The rats were allowed free access to rat chow
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Daily vaginal smears were taken at 10:00 AM, and the
stage of estrous cycle was determined. Overnight caging of
a proestrous female with a male of proven fertility
induced pregnancy. The next day, the presence of a vaginal
plug or spermatozoa in the vaginal smear was designated
as day 1 of pregnancy.
Pseudopregnancy was induced by electrical stimulation of
the cervix at proestrous, as reported earlier [26]. The next
day was considered day 1 of pseudopregnancy.
Collection of embryos
Zygotes were flushed with rat 1-cell embryo culture
medium (R1ECM) [26] from oviducts at day-1 of preg-
nancy. All equipment and media used were sterile. Ovary-
oviduct complexes were removed from anesthetized ani-
mals. The complexes were placed in R1ECM, and the ovi-
ducts were separated under a dissecting microscope. 30-
gauge blunt end needle attached to a syringe containing
R1ECM was inserted through the oviductal end held by
forceps surrounding needle and tube. Zygotes in their
cumulus mass were flushed and the cumulus cells were
removed by gentle aspiration through a micropipette
150–200 μm in diameter several times in R1ECM contain-
ing 80 U/ml of hyaluronidase. Clean zygotes were washed
3 times by transferring them into fresh R1ECM to remove
traces of hyaluronidase. Flushed zygotes were collected
with a mouth-controlled micropipette 150–200 μm in
diameter and transferred to the culture dishes.
Embryo culture
Clean zygotes were grown in-vitro to the developmental
stages of two-cell, four-cell, eight-cell, morula and blasto-
cyst. Each group of embryos consisted of 25–35 embryos
collected from six pregnant females. This was repeated
three times for each developmental stage (total of about
90 embryos per stage). Groups of 25–35 zygotes were
placed into 35-mm-diameter culture dishes (Nunc Co.,
Denmark) containing 50 μl of R1ECM medium under a
layer of mineral oil (previously equilibrated to the exper-
imental conditions) and cultured at 37°C under 5% CO2
in air (control group). This medium was shown by Miy-
oshi et al. [26] to enable cultured rat embryos to reach the
blastocyst stage. In comparing various media, at our labo-
ratory R1ECM was found to be the best medium to enable
a synchronous development of embryos (95% of total) to
the blastocyst stage. The developing embryos seemed to
be normal in their morphology, with almost no fragmen-
tation.
In the experimental group, EGF (Sigma) was added to the
medium in a final concentration of 10 ng/ml. In every
developmental stage embryos from control and experi-
mental group were collected, washed 3 times in fresh
R1ECM and used for immunofluorescence study. Three
pools of 50–60 embryos at the developmental stages of 2-
cell, 8-cell, morula and blastocyst were collected in 50 μl
aliquots of fresh R1ECM and stored at -70°C for PAs activ-
ity assay.
Embryo immunohistochemistry
The method used was basically that of Dubey et al. [27]
with various modifications. Groups of 20–25 embryos at
different developmental stages from the experimental and
control groups were fixed in 4% paraformaldehyde in
phosphate buffered saline (PBS) at room temperature and
washed twice in PBS, PH 7.4 for 5 minutes. Five percent
bovine serum albumin (BSA) in PBS was used for dilution
of antibodies and washings (PBS-BSA). The embryos were
washed four times in PBS-BSA before immunoreactions.
Embryos, randomly chosen were either exposed to poly-
clonal rabbit anti rodent uPA or rabbit anti rat tPA (Amer-
ican Diagnostics, Pendelton, IN) at a concentration of 4
μg/ml. Embryos were then incubated overnight in 50 μl of
each antibody solution under paraffin oil in a 35 mm cul-
ture plate in a moist chamber at 4°C. The embryos were
then washed four times in PBS-BSA and incubated with
Cy3-conjugated goat anti-rabbit IgG (Jackson ImmunoRe-
search Laboratories, Inc., West Grove, PA) at 37°C for 60
minutes. The conjugated antibody was used at a dilution
of 1:300 in PBS-BSA. After incubation with the secondary
antibody, the embryos were washed again in PBS-BSA and
stained with DNA stain 4', 6-diamidino-2-phenylindole
(DAPI) (Vector Laboratories, Burlingame, CA) and
mounted in Flouromount – G (Southern Biotechnology
Associates, Inc. Birmingham, AL) to minimize quenching.
To confirm that the fluorescence observed was neither
attributable neither to nonspecific binding of the second-
ary antibody nor to formaldehyde-induced autofluores-
cence, negative controls (without primary antibody) were
established during each immunoreaction procedure. The
immunocytochemistry staining procedure was repeated
three times for each stage of embryo development on dif-
ferent batches of embryos.
Image analysis
The distribution and concentration of PAs in the embryos
were visualized by fluorescent microscopy on a Zeiss laser
scanning confocal microscope equipped with an ×100
objective. Z-sections and XZ-sections were obtained from
3D scanning by using LSM510 software (Zeiss, Feldbach,
Switzerland). The PAs density for each embryo was com-
puted by image analysis based on the same principles as
manual counting described elsewhere [27]. The embryos'
fluorescent images were downloaded using image analysis
software, ImagJ (NIH, Bethesda, MD). These images were
stored in the computer by use of pixels. All the slices
obtained from 3D scanning were of 0.7 μm and were ana-
lyzed by counting the number of pixels of the Cy3 (red
color) in the whole slice. Total pixels in a whole embryoReproductive Biology and Endocrinology 2007, 5:4 http://www.rbej.com/content/5/1/4
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were calculated by summing the number of pixels in all
the slices of an embryo. This method showed the total
amount of PAs expression in each embryo. The number of
pixels in an embryo represents the intensity of PAs stain-
ing (fluorescence), which is in turn proportional to the
amount of PAs in that embryo. Each experimental group
consisted of 8–10 embryos and the measurements
repeated three times with different batches of embryos
from each developmental stage stained at different times
(total number of 24–30 embryos per stage).
Enzymatic assay for plasminogen activators
A chromogenic assay, as described originally by Coleman
and Green [28] with some modifications to enable meas-
urement of embryonic PAs' activities was used. This assay
measures total plasminogen activator activity without dif-
ferentiating between tPA and uPA. The uPA inhibitor ami-
loride was used to differentiate between the relative
activity of uPA and tPA.
Three frozen 50 μl aliquots, from each stage, containing a
total of approximately 160 embryos were thawed, pooled,
and lysed by repeated freezing and thawing in R1ECM.
Each such pool was divided to 4 aliquots (containing
lysed material equivalent to 37–40 embryos). Lysed
embryos and endometrial extract samples were mixed
with, or without (negative control) 2.5 μg plasminogen
and with or without the uPA inhibitor amiloride (Sigma,
St. Louis, MO) to reach a final volume of 50 μl. The mix-
ture was incubated at 37°C for 60 minutes. At the end of
this incubation, 1 ml of a solution, containing 220 μM
5,5'-dithiobis (2-nitrobenzoic acid) and 220 μM thioben-
zyl benzylcarboxycarbonyl-L-lyzinate (Sigma) in phos-
phate buffer was added, and the incubation was
continued for another 60 minutes. The absorbance at 410
nm was indicative of PAs activity. Standard curves of uPA
activity (American diagnostics), ranging from 0.02 to 4
mIU, were included in each assay to estimate PAs activity.
The sensitivity of the assay under the conditions described
above was 0.02 ± 0.01 mIU. No PAs activity was detected
in the absence of plasminogen (negative control). The
above measurements were repeated three times for each
experimental group.
Embryo transfer
Embryo transfer was done as previously described by
Hogan et al. [29] and by Ertzeid and Storeng [30]. Seven-
teen pseudopregnant female rats at day-5 of pseudopreg-
nancy were anesthetized by i.p. injection of chloral
hydrate 10% (w/v; 0.003 ml/g body mass) and the uterine
horns were exposed via lateral incisions. Blastocysts to be
transferred were collected from EGF supplemented in-
vitro grown blastocysts or controls. Blastocysts were col-
lected with a mouth-controlled pipette with a curved tip,
150–200  μm in diameter. The tip of the pipette was
inserted into a hole made previously by inserting 23-
gauge needle through the uterine wall at the oviductal
end. Five EGF treated or 5 controls were transferred in a
minimal volume of 5 μl, at random, into either of the con-
tralateral uterine horns of the pseudadin-77@smile.neto-
pregnant recipient. Thereafter, the uterine horns were
replaced in the abdominal cavity. After suturing the
abdominal muscles, the skin incision was closed using
metal clips. The recipients were euthanized by i.p. over-
dose injection of chloral hydrate. Implantation rate was
determined by counting implanted embryos 9 days after
transfer.
Statistical analysis
Data are expressed as means ± SEM. Statistical analysis
was performed using paired "t"-test or two-way analysis of
variance (ANOVA) followed by the least significant differ-
ences (LSD) test for multiple comparisons. P < 0.05 was
defined as statistically significant difference.
Results
Immunolocalization of tPA and uPA in preimplantation 
embryos; effect of EGF
Immunohistochemical staining for the location of tPA
and uPA in preimplantation embryos developed in-vitro
with or without exogenous EGF are shown in figure 1.
Plasminogen activators were detected in all the embryonic
developmental stages in-vitro (from the two cell stage to
the blastocyst stage) both in the presence of exogenous
EGF and in controls (Fig. 1A-T). The uPA was detected in
the cell cytoplasm and plasma membrane (Fig. 1A-J)
while tPA was detected on the cell membrane and in the
perivitelline space (Fig. 1K-T). In the blastocyst stage, both
with and without EGF, PAs were localized mainly in the
trophectoderm (Fig. 1E,J,O,T). There were no differences
in PAs localization in the presece of EGF, between any of
the stages of development.
Effect of exogenous EGF on the level of PAs expression at 
different embryonic developmental stages
Quantitative measurment of total uPA in a whole embryo
at different developmental stages showed significantly
higher expression in in-vitro developed embryos in the
presence of exogenous EGF in the 2-cell, 4-cell, morula
and blastocyst stages compared to the control groups
(140%, 188%, 94% and 185%, respectively. P < 0.01)
(Fig. 2A). In contrast, the highest expression of uPA in the
control developed embryos was found at the 8-cell stage
(55.2 × 103 Pixels per embryo). In the presence of exoge-
nous EGF, highest expression of uPA was found at the 2-
cell stage (84.9 × 103 Pixels per embryo) which then
decreased gradually towards the blastocyst stage (44.75 ×
103 Pixels per embryo) (Fig. 2A).Reproductive Biology and Endocrinology 2007, 5:4 http://www.rbej.com/content/5/1/4
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Immunolocalization of uPA and tPA in preimplantation developing rat embryos grown in-vitro with and without the presence  of 10 ng/ml EGF in the medium Figure 1
Immunolocalization of uPA and tPA in preimplantation developing rat embryos grown in-vitro with and without the presence 
of 10 ng/ml EGF in the medium. (A, F, K, P), 2-cells. (B, G, L, Q), 4-cells. (C, H, M, R), 8-cells. (D, I, N, S), Morula. (E, J, O, T), 
Blastocyst. (A-E), uPA -EGF. (F-J), uPA +EGF. (K-O), tPA -EGF. (P-T), tPA +EGF.
K  A F  P 
L B G  Q 
M C H  R 
N D I  S 
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Quantitative (Pixels/embryos) uPA expression in preimplantation rat embryos developed in-vitro with and without the pres- ence of EGF in the medium (A) Figure 2
Quantitative (Pixels/embryos) uPA expression in preimplantation rat embryos developed in-vitro with and without the pres-
ence of EGF in the medium (A). Quantitative (Pixels/embryos) tPA expression in preimplantation rat embryos developed in-
vitro with and without the presence of EGF in the medium (B). Means ± SEM. Different letters above the columns represent 
significant differences (ANOVA followed by LSD test, P < 0.01).
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Total tPA expression in a whole embryo showed highest
expression in embryos developed in the presence of exog-
enous EGF at the 8-cell stage in comparison to the con-
trols (69.28 and 40.1 × 103 Pixels per embryo,
respectively, see Fig. 2B). In all the other developmental
stages the addition of exogenous EGF did not affect the
total amount of tPA in the cultured embryos.
The effect of exogenous EGF on the activity of PAs in 
preimplantation embryos
The uPA activity (fig. 3A) in the control embryos was low
in the 2-cell stage (103.28 μIU/embryo) and increased
gradually towards the blastocyst stage (299.86 μIU/
embryo, p < 0.01). The same pattern of increase in uPA
activity was found in the presence of exogenous EGF with
significantly higher activity in 8-cell, morula and blasto-
cyst stages (66.7%, 37.3% and 54% respectively, p < 0.05)
(Fig. 3A).
The tPA activity did not change significantly during in-
vitro embryo development of the control (111.24–137.16
μIU/embryo, p < 0.05, see Fig. 3B).
At the 8-cell stage there was a significant increase in tPA
activity in embryos developed with the addition of exoge-
nous EGF (205.84 μIU/embryo, p < 0.05, see Fig. 3B).
Effect of exogenous EGF on embryo implantation rate
The implantation rate of in-vitro developing blastocysts,
with or without the presence of exogenous EGF, was stud-
ied using 17 pseudopregnant rats. Five developed blasto-
cysts from each experimental group were transferred into
each of the contralateral uterine horns (total of 85
embryos from each group). The implantation rate of the
control developing blastocysts was significantly low as
compared with that of blastocysts developed in the pres-
ence of exogenous EGF (31.7% and 68.2% respectively, p
< 0.01. Fig. 4)
Discussion
The purpose of this study was to examine the effect of EGF
on PA proteins expression (cellular distribution and
quantity) and activity in in-vitro developing rat preim-
plantation embryos.
In our previous study we found that in rat embryos, uPA
and tPA were present in all the stages of preimplantation
development [24]. Other previous animal studies have
demonstrated differential expression of PAs activity in cul-
tured mouse embryos with greatest expression in early
gestation [31]. Also, Zhang et al. [32] reported expression
of uPA gene and uPA activity in preimplantation rat
embryos developed in-vitro. Khamsi et al. [14] reported
the presence of mRNA for uPA in human blastocysts.
These cumulated observations hypothesize that PAs may
be involved in extracellular matrix modification during
preimplantation embryo development and implantation.
However, information about the expression and immu-
nolocalization of uPA and tPA have not been reported in
in-vitro preimplantation developing rat embryos grown
in EGF supplemented culture medium.
Quantitative measurements of PAs expression in a whole
embryo enabled us to compare embryos at different devel-
opmental stages and different growth conditions as
shown in our previous study [24]. Immunoreactive uPA
was present in the embryonic cell cytoplasm and plasma
membranes in all developmental stages, grown with or
without EGF in the medium, while tPA was detected on
the plasma membranes and in the perivitelline spaces.
These results are supported by Zhang et al. [32] who
showed that PAs activity was detected in oocytes and
embryos between the 2-cell and blastocyst stages. In blas-
tocysts developed in-vitro, with or without EGF, PAs were
localized mainly in the trophectoderm and these findings
are in agreement with previous observations, showing an
increase in uPA activity towards the blastocyst stage in in-
vivo and in in-vitro developing embryos [33]. The pres-
ence of uPA in the trophectoderm combined with its high
activity in this stage supports the idea that blastocyst uPA
activity is important for implantation, thus, inhibition of
PAs decreases the extent of trophoblast attachment and
outgrowth in-vitro [34]. Sappino et al. [7] showed that tro-
phoblast cells grown in-vitro possesed PAs activity at the
normal time of their penetration into the endometrium
in-vivo. The uPA was the major enzyme secreted from tro-
phectoderm cells with the highest activity on days five to
seven of pregnancy. In addition, in implantation-defective
rats, uPA activity and extra-cellular matrix degradation
were reduced as compared with intact animals [11]. All
the above support the assumption that uPA activity is
important for the implantation process.
Pro-uPA is synthesized as an inactive single chain that can
be stored or secreted. The secreated pro-uPA can be
cleaved to produce the two-chain active molecule uPA, by
the aid of limited proteolytic activity of plasmin [35]. Pro-
uPA or uPA can be found free in the cytoplasm and the
extracellular matrix or bound to a membrane uPA recep-
tor [36]. Whether the uPA identified in this study is pro-
uPA or uPA is unknown since the immunofluorescence
staining method used cannot distinguish between the
two. There is no correlation between the level of activity
and the measured quantity of uPA in either EGF treated
embryos or in the control ones. This could be explained
by yet undetermined variations in the ratio of active and
inactive forms of uPA.
The in-vivo conditions within the oviduct and uterine cav-
ity constitute the optimal environment providing notReproductive Biology and Endocrinology 2007, 5:4 http://www.rbej.com/content/5/1/4
Page 8 of 11
(page number not for citation purposes)
Activity of uPA in preimplantation embryos developed in-vitro with and without the presence of EGF in the medium (A) Figure 3
Activity of uPA in preimplantation embryos developed in-vitro with and without the presence of EGF in the medium (A). Activ-
ity of tPA in preimplantation embryos developed in-vitro with and without the presence of EGF in the medium (B). Means ± 
SEM. Different letters above the columns represent significant differences (ANOVA followed by LSD test, P < 0.01).
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only proper temperature, pH and ion concentrations, but
also the crucial amount of nutrients and growth factors
[37]. Studying animal models suggested that growth fac-
tors are embryotrophic [38] and EGF may promote preim-
plantation embryo growth [39,40], as well as trophoblast
invasion and postimplantation embryo growth [41,42].
In addition, growth factors' receptors are localized on
blastomeres of mammals preimplantation embryos
[17,43,44]. These receptors appear in the apical blast-
omeres' membrane of the 4-cell stage mouse embryos
[17]. Several reports have demonstrated the effect of EGF
on embryo development, but very little is known about its
effect on the ability of in-vitro developing embryos to
implant.
The activity of PAs system in various tissues is under hor-
monal and cytokine control. Because angiogenesis
requires proteolysis, several angiogenetic factors have
been shown to promote activity of the PAs system. Kasza
and Koj found that EGF enhances uPA, tPA and PAI-1
expression in astrocytoma cells [45]. In addition, Li et al.
showed that in endothelial cells and monocytes uPA up-
regulates itself via its EGF domain and uPA receptor [46].
The expression of EGF and its receptor in trophoblasts
together with the marked proteolytic activity in the pla-
cental bed suggests an interaction between the two sys-
tems; therefore we studied the effect of EGF on the activity
of PA enzymes in preimplantation embryos, and its effect
on implantation rate.
In the present study, preimplantation embryos grown in-
vitro with EGF, showed a quantitative increase in PAs
expression. There was a significant increase in the quantity
of uPA in all developmental stages, except the 8-cell stage.
The addition of EGF did not change the cellular distribu-
tion of PAs in the in-vitro developing preimplantation
embryos. At the 8-cell stage only, there was an increase in
tPA quantity. The data hypothesize that EGF affects
embryonic PAs expression and activity in a stage specific
and activator (uPA or tPA) specific manner. The signifi-
cant increase in embryonic uPA content detected in the 2-
cell stage, in the presence of EGF, hypothesize the recog-
nition of EGF at this early developmental stage by apical
blastomeres membrane receptor in contrast to the finding
of Weliy et al. [17] who reported presence of EGF receptors
from the 4-cell stage.
The importance of uPA for the process of implantation is
re-enforced by its relocalization in the trophectoderm
cells. Despite the increased concentration of tPA in the
trophectoderm cells, its activity in the blastocyst stage is
reduced, raising the hypothesis that it may be in an inac-
tive enzyme form in this stage which is indistinguishable
in the immunostaining method used [24].
Embryonic PAs activities were detected in all the stages of
the in-vitro preimplantation embryo development in
either EGF treated or untreated embryos. The embryonic
genome of rats and mice starts to be expressed at the 2-cell
stage [47] and the presence of PAs already in this early
stage may be a consequence of this activation. The enzyme
tPA attaches to a cell membrane receptor, annexin II, thus
directing the proteolytic activity to selected extracellular
regions [48]. Such attachment of tPA from maternal
source could also, at least partially, contributes to the
presence of tPA found in the early developmental stages.
The embryonic extracellular matrix is in a continuous
turnover during the embryonic development. The 8-cell
stage is characterized by structural changes taking place in
Percentage of implanted embryos in contralateral uterine  horns of 17 pseudopregnant rats into which in-vitro devel- oped blastocysts with and without the presence of EGF in  the medium were transferred Figure 4
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the embryo during the compaction process. It is therefore
likely that the tPA effect on the remodeling taking place in
the 8-cell stage is more sensitive to the presence of EGF.
The increase in tPA expression from the 2-cell stage to the
4-cell stage in both EGF treated and untreated embryos, is
probably due to de novo synthesis of tPA since there is no
extraembryonic tPA source but the embryos in the culture.
The increased tPA activity at the 8-cell stage could be due
to the increased immunoreactive tPA quantity measured
at this stage.
The uPA activity gradually rises from the early develop-
mental stages up to the blastocyst stage. Such high activity
in the blastocyst stage at the normal time of nidation and
implantation may indicate its importance in these proc-
esses. These data suport the finding of Axelrod regarding a
correlation between aberrant implantation in rats and low
uPA activity and extra-cellular matrix degradation as com-
pared with intact animals [11]. In addition, Kubo et al.
[34] showed that inhibition of PAs activity prevents the
adhesion of mice embryos to decidual cells grown in-
vitro.
Higher PAs activity was observed in in-vitro developed
embryos in the presence of EGF as compared with control
ones. This could be explained by a reduced metabolic
activity in the control developed embryos [49].
The present results confirm the importance of EGF in
modulating the PA/plasmin system in the embryo during
preimplantation development. Wiley et al. [17] showed
expression of EGF receptor mRNA in preimplantation
embryos which hypothesize that EGF may act directly on
embryos, perhaps in a paracrine manner. These observa-
tions suggest specific regulation of proteinase activity in
blastocyst that is independent on the mitogenic effects of
EGF. Upon visual inspection, the sizes of blastocysts were
similar in EGF-treated and untreated cultures. This does
not entirely exclude the possibility that increased expres-
sion of proteinase activity could be due increased cell
numbers (proliferation) in response to EGF.
Previous work demonstrated significant lower implanta-
tion rate of in-vitro developed embryos compared to in-
vivo ones in the rat [33]. In this work we have compared
the implantation rate of in-vitro developed blastocysts
with or without the addition of EGF. Culturing the
embryos in-vitro with EGF significantly increased their
implantation rate. This finding is in accordance with
Morita et al. [50] who showed a significant increase in
implantation rate of in-vitro developed mice blastocysts
treated with EGF.
Our data suggest that development in-vitro, which is mor-
phologicaly indistinguishable from that in-vivo, may
impair embryo quality and thus reduce implantation rate,
independent of the endometrial condition of the recipi-
ent. This embryo donation model may provide a way of
determining whether a developmental failure may be a
result of the in-vitro conditions. It is conceivable that the
presence of EGF in the reproductive tract would enhance
the quality of embryos developed in-vivo. Indeed, oviduct
epithelium is known to promote embryogenesis in many
mammalian species and the expression of EGF in the ovi-
duct and its involvement in early embryo development
has been reported [51-53].
Conclusion
In conclusion, addition of EGF to the culture medium
increases uPA activity and embryo implantation rates in
the rat.
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